BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 27815961)

  • 1. Successful treatment of a child with a prolactin secreting macroadenoma with temozolomide.
    Felker J; Patterson B; Wrubel D; Janss A
    J Pediatr Endocrinol Metab; 2016 Dec; 29(12):1413-1415. PubMed ID: 27815961
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Failure of a second temozolomide cycle in a patient with a prolactin-secreting pituitary carcinoma.
    Bilbao I; Egaña N; García C; Olaizola I
    Endocrinol Diabetes Nutr; 2017 Dec; 64(10):564-566. PubMed ID: 29137963
    [No Abstract]   [Full Text] [Related]  

  • 3. Temozolomide therapy in a man with an aggressive prolactin-secreting pituitary neoplasm: Morphological findings.
    Kovacs K; Horvath E; Syro LV; Uribe H; Penagos LC; Ortiz LD; Fadul CE
    Hum Pathol; 2007 Jan; 38(1):185-9. PubMed ID: 17056093
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Temozolomide retreatment in a recurrent prolactin-secreting pituitary adenoma: Hormonal and radiographic response.
    Strowd RE; Salvatori R; Laterra JJ
    J Oncol Pharm Pract; 2016 Jun; 22(3):517-22. PubMed ID: 25616657
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of aggressive prolactinoma with temozolomide: A case report and review of literature up to date.
    Chen C; Yin S; Zhang S; Wang M; Hu Y; Zhou P; Jiang S
    Medicine (Baltimore); 2017 Nov; 96(47):e8733. PubMed ID: 29381964
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A mechanism of acquiring temozolomide resistance during transformation of atypical prolactinoma into prolactin-producing pituitary carcinoma: case report.
    Murakami M; Mizutani A; Asano S; Katakami H; Ozawa Y; Yamazaki K; Ishida Y; Takano K; Okinaga H; Matsuno A
    Neurosurgery; 2011 Jun; 68(6):E1761-7; discussion E1767. PubMed ID: 21389894
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Temozolomide in the treatment of an invasive prolactinoma resistant to dopamine agonists.
    Neff LM; Weil M; Cole A; Hedges TR; Shucart W; Lawrence D; Zhu JJ; Tischler AS; Lechan RM
    Pituitary; 2007; 10(1):81-6. PubMed ID: 17285366
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early Recognition and Initiation of Temozolomide Chemotherapy for Refractory, Invasive Pituitary Macroprolactinoma with Long-Term Sustained Remission.
    Barkhoudarian G; Palejwala SK; Ogunbameru R; Wei H; Eisenberg A; Kelly DF
    World Neurosurg; 2018 Oct; 118():118-124. PubMed ID: 30031177
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Temozolomide therapy for resistant prolactin-secreting pituitary adenomas and carcinomas: a systematic review.
    Almalki MH; Aljoaib NN; Alotaibi MJ; Aldabas BS; Wahedi TS; Ahmad MM; Alshahrani F
    Hormones (Athens); 2017 Apr; 16(2):139-149. PubMed ID: 28742502
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Successful treatment of leptomeningeally metastasised pituitary carcinoma with temozolomide.
    van der Vlist A; Snijders TJ; Stades AME; Spliet WGM; De Vos FYFL
    Neth J Med; 2017 Dec; 75(10):451-454. PubMed ID: 29256415
    [TBL] [Abstract][Full Text] [Related]  

  • 11. What causes a prolactinoma to be aggressive or to become a pituitary carcinoma?
    Phillips J; East HE; French SE; Melcescu E; Hamilton RD; Nicholas WC; Fratkin JF; Parent AD; Luzardo G; Koch CA
    Hormones (Athens); 2012; 11(4):477-82. PubMed ID: 23422771
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel use of temozolomide in a patient with malignant prolactinoma.
    Byrne S; Karapetis C; Vrodos N
    J Clin Neurosci; 2009 Dec; 16(12):1694-6. PubMed ID: 19818629
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dopamine agonist-resistant prolactinomas.
    Oh MC; Aghi MK
    J Neurosurg; 2011 May; 114(5):1369-79. PubMed ID: 21214334
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Temozolomide treatment of a pituitary carcinoma and two pituitary macroadenomas resistant to conventional therapy.
    Hagen C; Schroeder HD; Hansen S; Hagen C; Andersen M
    Eur J Endocrinol; 2009 Oct; 161(4):631-7. PubMed ID: 19654234
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Temozolomide treatment in aggressive pituitary tumors and pituitary carcinomas: a French multicenter experience.
    Raverot G; Sturm N; de Fraipont F; Muller M; Salenave S; Caron P; Chabre O; Chanson P; Cortet-Rudelli C; Assaker R; Dufour H; Gaillard S; François P; Jouanneau E; Passagia JG; Bernier M; Cornélius A; Figarella-Branger D; Trouillas J; Borson-Chazot F; Brue T
    J Clin Endocrinol Metab; 2010 Oct; 95(10):4592-9. PubMed ID: 20660056
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antitumour effects of temozolomide in a man with a large, invasive prolactin-producing pituitary neoplasm.
    Syro LV; Uribe H; Penagos LC; Ortiz LD; Fadul CE; Horvath E; Kovacs K
    Clin Endocrinol (Oxf); 2006 Oct; 65(4):552-3. PubMed ID: 16984254
    [No Abstract]   [Full Text] [Related]  

  • 17. Long-term control of a MEN1 prolactin secreting pituitary carcinoma after temozolomide treatment.
    Philippon M; Morange I; Barrie M; Barlier A; Taieb D; Dufour H; Conte-Devolx B; Brue T; Castinetti F
    Ann Endocrinol (Paris); 2012 Jun; 73(3):225-9. PubMed ID: 22520146
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Case Report: Temozolomide Treatment of Refractory Prolactinoma Resistant to Dopamine Agonists.
    Tang H; Cheng Y; Huang J; Li J; Zhang B; Wu ZB
    Front Endocrinol (Lausanne); 2021; 12():616339. PubMed ID: 33776913
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Temozolomide and pituitary adenoma.
    Hueng DY; Ma HI; Sytwu HK; Liu MY
    J Neurosurg; 2011 Jun; 114(6):1820: author reply 1820-1. PubMed ID: 21513431
    [No Abstract]   [Full Text] [Related]  

  • 20. How effective is temozolomide for treating pituitary tumours and when should it be used?
    Halevy C; Whitelaw BC
    Pituitary; 2017 Apr; 20(2):261-266. PubMed ID: 27581836
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.